000834118 001__ 834118
000834118 005__ 20210129230543.0
000834118 0247_ $$2doi$$a10.1016/j.ymeth.2017.05.019
000834118 0247_ $$2ISSN$$a1046-2023
000834118 0247_ $$2ISSN$$a1095-9130
000834118 0247_ $$2pmid$$apmid:28552264
000834118 0247_ $$2WOS$$aWOS:000414879700014
000834118 037__ $$aFZJ-2017-04118
000834118 082__ $$a540
000834118 1001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b0$$eCorresponding author$$ufzj
000834118 245__ $$aImaging of amino acid transport in brain tumours: Positron emission tomography with O-(2-[ 18 F]fluoroethyl)- L -tyrosine (FET)
000834118 260__ $$aOrlando, Fla.$$bAcademic Press$$c2017
000834118 3367_ $$2DRIVER$$aarticle
000834118 3367_ $$2DataCite$$aOutput Types/Journal article
000834118 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1510063018_4901
000834118 3367_ $$2BibTeX$$aARTICLE
000834118 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000834118 3367_ $$00$$2EndNote$$aJournal Article
000834118 520__ $$aThe assessment of cerebral gliomas using magnetic resonance imaging (MRI) provides excellent structural images but cannot solve all diagnostic problems satisfactorily. The differentiation of tumour tissue from non-neoplastic changes may be difficult especially in the post-treatment phase. In recent years, positron emission tomography (PET) using radiolabelled amino acids has gained considerable interest as an additional tool to improve the diagnosis of cerebral gliomas and brain metastases. A key step for this advancement was the development of the F-18 labelled amino acid O-(2-[18F]fluoroethyl)-L-tyrosine (FET) which has spread rapidly in the last decade and replaced carbon-11 labelled amino acid tracers such as 11C-methyl-L-methionine (MET) in many centres in Europe. FET can be produced with high efficiency and distributed in a satellite concept like 2-[18F]fluoro-2-deoxy-D-glucose (FDG). Furthermore, FET exhibits favourable properties such as high in vivo stability, high tumour to background contrast and tissue specific tracer kinetics, which provides additional information for tumour grading or differential diagnosis. The Response Assessment in Neuro-Oncology (RANO) working group — an international effort to develop new standardized response criteria for clinical trials in brain tumours — has recently recommended the additional use of amino acid PET imaging for brain tumour management. FET PET can provide important diagnostic information in crucial situations such as the definition of biopsy site, the delineation of cerebral gliomas for therapy planning, sensitive monitoring of treatment response and an improved differentiation of tumour recurrence from treatment-related changes. In this article the basic information, methodological aspects and the actual status of clinical application of FET PET are reviewed.
000834118 536__ $$0G:(DE-HGF)POF3-573$$a573 - Neuroimaging (POF3-573)$$cPOF3-573$$fPOF III$$x0
000834118 588__ $$aDataset connected to CrossRef
000834118 7001_ $$0P:(DE-Juel1)131627$$aStoffels, Gabriele$$b1$$ufzj
000834118 7001_ $$0P:(DE-Juel1)141877$$aFilss, Christian$$b2$$ufzj
000834118 7001_ $$0P:(DE-Juel1)132315$$aHeinzel, Alexander$$b3$$ufzj
000834118 7001_ $$0P:(DE-Juel1)156479$$aStegmayr, Carina$$b4
000834118 7001_ $$0P:(DE-Juel1)145110$$aLohmann, Philipp$$b5$$ufzj
000834118 7001_ $$0P:(DE-Juel1)144347$$aWilluweit, Antje$$b6$$ufzj
000834118 7001_ $$0P:(DE-Juel1)166419$$aNeumaier, Bernd$$b7$$ufzj
000834118 7001_ $$0P:(DE-Juel1)132318$$aMottaghy, Felix M.$$b8$$ufzj
000834118 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b9$$ufzj
000834118 773__ $$0PERI:(DE-600)1471152-7$$a10.1016/j.ymeth.2017.05.019$$gp. S1046202316303103$$p124-134$$tMethods$$v130$$x1046-2023$$y2017
000834118 8564_ $$uhttps://juser.fz-juelich.de/record/834118/files/1-s2.0-S1046202316303103-main.pdf$$yRestricted
000834118 8564_ $$uhttps://juser.fz-juelich.de/record/834118/files/1-s2.0-S1046202316303103-main.gif?subformat=icon$$xicon$$yRestricted
000834118 8564_ $$uhttps://juser.fz-juelich.de/record/834118/files/1-s2.0-S1046202316303103-main.jpg?subformat=icon-1440$$xicon-1440$$yRestricted
000834118 8564_ $$uhttps://juser.fz-juelich.de/record/834118/files/1-s2.0-S1046202316303103-main.jpg?subformat=icon-180$$xicon-180$$yRestricted
000834118 8564_ $$uhttps://juser.fz-juelich.de/record/834118/files/1-s2.0-S1046202316303103-main.jpg?subformat=icon-640$$xicon-640$$yRestricted
000834118 8564_ $$uhttps://juser.fz-juelich.de/record/834118/files/1-s2.0-S1046202316303103-main.pdf?subformat=pdfa$$xpdfa$$yRestricted
000834118 909CO $$ooai:juser.fz-juelich.de:834118$$pVDB
000834118 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b0$$kFZJ
000834118 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131627$$aForschungszentrum Jülich$$b1$$kFZJ
000834118 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)141877$$aForschungszentrum Jülich$$b2$$kFZJ
000834118 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132315$$aForschungszentrum Jülich$$b3$$kFZJ
000834118 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)156479$$aForschungszentrum Jülich$$b4$$kFZJ
000834118 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145110$$aForschungszentrum Jülich$$b5$$kFZJ
000834118 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)144347$$aForschungszentrum Jülich$$b6$$kFZJ
000834118 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b7$$kFZJ
000834118 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132318$$aForschungszentrum Jülich$$b8$$kFZJ
000834118 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b9$$kFZJ
000834118 9131_ $$0G:(DE-HGF)POF3-573$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vNeuroimaging$$x0
000834118 9141_ $$y2017
000834118 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000834118 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000834118 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000834118 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000834118 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMETHODS : 2015
000834118 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000834118 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000834118 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000834118 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000834118 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000834118 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000834118 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000834118 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000834118 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000834118 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x0
000834118 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x1
000834118 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x2
000834118 9201_ $$0I:(DE-82)080010_20140620$$kJARA-BRAIN$$lJARA-BRAIN$$x3
000834118 980__ $$ajournal
000834118 980__ $$aVDB
000834118 980__ $$aI:(DE-Juel1)INM-4-20090406
000834118 980__ $$aI:(DE-Juel1)INM-3-20090406
000834118 980__ $$aI:(DE-Juel1)INM-5-20090406
000834118 980__ $$aI:(DE-82)080010_20140620
000834118 980__ $$aUNRESTRICTED